Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator

This article was originally published in The Pink Sheet Daily

Executive Summary

While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.

You may also be interested in...



Six Devices, Diagnostics Among Cleveland Clinic’s Top 10 Innovations

At its 2013 Innovation Summit, the Cleveland Clinic unveiled six devices and diagnostics among its top 10 innovations.

Medicare Bonus Payments Awarded To Cook’s Stent, Second Sight’s Eye Implant

Cook Medical’s Zilver PTX stent and Second Sight Medical Products’ Argus II retinal prosthesis system will enjoy new-technology add-on payments in 2014 under CMS’ hospital inpatient prospective payment system final rule.

FDA Advisory Panel Supports NeuroPace’s RNS Neurostimulator

Neurological devices panel votes in favor of device intended to reduce epileptic seizures despite lingering questions about the trial results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel